N/A N=26 The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery
Ecchymosis
Primary: Assess Extent of Bruising — .617; .736 a ratio of pixels
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=53 Efficacy of Arnica Montana in Reducing Postoperative Edema and Pain
Arnica · Third Molar Extraction
Primary: Change in Postoperative Facial Swelling From Baseline to Day 3 — 9.2508; 9.3320; 7.4336; 7.0346 cm^2
N/A N=16 Effects of Topical Vitamin K, Vitamin K and Retinol, and Arnica on Post-Laser Bruising
Ecchymosis
Primary: Average Bruise Change — -3.68; -3.71; -3.88; -4.13 Units on a Scale
Phase 3 N=420 TAASS-Traumeel Ointment and Gel Compared With a Topical NSAID in Athletes With Acute Ankle Sprain
Sprain of Ankle
Primary: Patient's Assessment of Ankle Pain (VAS)- Absolute Value Decrease on Day 7 — -33.00; -37.10; -37.10 Absolute value units on a scale VAS
Phase 2 N=164 Bonipar for Acute and Chronic Musculoskeletal Pain
Chronic Pain · Musculoskeletal Pain
Primary: Change in Pain as Measured by Subjective Pain Intensity Rating (SPIR) — -2.3; -2.6 score on a scale — p=0.46
Phase 3 N=204 Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied Four Times Daily in Subjects With Acute Blunt Trauma Injuries
Acute Blunt Soft Tissue Injuries/Contusions
Primary: Pain on Movement — 33.1; 65.4 mm
Phase 3 N=302 Voltaren Emulgel 2% Acute Ankle Sprain Non Inferiority Study
Pain
Primary: Change From Baseline in Pain on Movement (POM) on Day 5 of Treatment as Assessed by a 100 Millimeter (mm) Visual Analogue Scale (VAS) — -42.36; -43.47 mm — p=0.5950
Phase 3 N=385 A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain
Pain
Primary: Area Under the Curve From Day 1 to Day 3 (AUC1-3 Days) of Pain Intensity(PI) on Movement for Diclofenac/Methanol Gel and Placebo Gel — 276.97; 282.88 NRS Score (0 - 10…